HomeCompareHUM vs PKI

HUM vs PKI: Dividend Comparison 2026

HUM yields 2.13% · PKI yields 0.24%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HUM wins by $69.7K in total portfolio value
10 years
HUM
HUM
● Live price
2.13%
Share price
$166.00
Annual div
$3.54
5Y div CAGR
46.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$89.4K
Annual income
$29,002.59
Full HUM calculator →
PKI
PKI
● Live price
0.24%
Share price
$115.24
Annual div
$0.28
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.7K
Annual income
$0.02
Full PKI calculator →

Portfolio growth — HUM vs PKI

📍 HUM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHUMPKI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HUM + PKI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HUM pays
PKI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HUM
Annual income on $10K today (after 15% tax)
$181.27/yr
After 10yr DRIP, annual income (after tax)
$24,652.20/yr
PKI
Annual income on $10K today (after 15% tax)
$20.65/yr
After 10yr DRIP, annual income (after tax)
$0.02/yr
At 15% tax rate, HUM beats the other by $24,652.18/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HUM + PKI for your $10,000?

HUM: 50%PKI: 50%
100% PKI50/50100% HUM
Portfolio after 10yr
$54.5K
Annual income
$14,501.31/yr
Blended yield
26.58%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PKI right now

HUM
Analyst Ratings
14
Buy
27
Hold
2
Sell
Consensus: Hold
Price Target
$235.00
+41.6% upside vs current
Range: $146.00 — $345.00
Altman Z
4.0
Piotroski
6/9
PKI
Analyst Ratings
13
Buy
18
Hold
Consensus: Hold
Price Target
$166.57
+44.5% upside vs current
Range: $145.00 — $202.00
Altman Z
2.9
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HUM buys
13
PKI buys
0
PoliticianChamberTickerTypeAmountDate
Julia Letlow🏢 House$HUM▼ Sell$1,001 - $15,0002026-02-10
Gilbert Cisneros🏢 House$HUM▼ Sell$1,001 - $15,0002025-11-12
Michael McCaul🏢 House$HUM▼ Sell$15,001 - $50,0002025-11-04
Lisa McClain🏢 House$HUM▲ Buy$1,001 - $15,0002025-09-25
Julia Letlow🏢 House$HUM▲ Buy$1,001 - $15,0002025-08-08
Gilbert Cisneros🏢 House$HUM▲ Buy$1,001 - $15,0002025-08-05
Ro Khanna🏢 House$HUM▲ Buy$1,001 - $15,0002025-07-25
Lisa McClain🏢 House$HUM▲ Buy$1,001 - $15,0002025-06-24
Gilbert Cisneros🏢 House$HUM▼ Sell$1,001 - $15,0002025-05-30
Gilbert Cisneros🏢 House$HUM▼ Sell$1,001 - $15,0002025-05-30
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHUMPKI
Forward yield2.13%0.24%
Annual dividend / share$3.54$0.28
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR46.1%-50%
Portfolio after 10y$89.4K$19.7K
Annual income after 10y$29,002.59$0.02
Total dividends collected$63.4K$24.00
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusHoldHold
Analyst price target$235.00$166.57

Year-by-year: HUM vs PKI ($10,000, DRIP)

YearHUM PortfolioHUM Income/yrPKI PortfolioPKI Income/yrGap
1← crossover$11,012$311.56$10,712$12.15+$300.00HUM
2$12,251$468.45$11,468$6.08+$783.00HUM
3$13,820$711.61$12,274$3.04+$1.5KHUM
4$15,883$1,096.11$13,135$1.52+$2.7KHUM
5$18,715$1,720.11$14,055$0.76+$4.7KHUM
6$22,793$2,767.44$15,039$0.38+$7.8KHUM
7$28,990$4,601.98$16,092$0.19+$12.9KHUM
8$39,012$7,992.19$17,218$0.10+$21.8KHUM
9$56,428$14,685.03$18,424$0.05+$38.0KHUM
10$89,380$29,002.59$19,713$0.02+$69.7KHUM

HUM vs PKI: Complete Analysis 2026

HUMHealthcare

Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, and home solutions services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2021, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.

Full HUM Calculator →

PKIStock

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Full PKI Calculator →
📬

Get this HUM vs PKI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HUM vs SCHDHUM vs JEPIHUM vs OHUM vs KOHUM vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.